Table 3.
Hemodynamic characteristics in the beginning of the intervention and change to 24 weeks
| Baseline | Change to 24 weeks | P-valuea | |||
|---|---|---|---|---|---|
| Placebo mean (s.d.) | Peptide mean (s.d.) | Placebo mean (95% CI) | Peptide mean (95% CI) | ||
| Aix, %-units | 20.0 (8.4) | 24.3 (8.4) | 1.20 (0.09 to 2.32) | −1.53 (−2.95 to −0.12) | 0.013 |
| AIx GTN, %-units | −3.82 (9.26) | 0.07 (9.73) | 1.20 (−0.74 to 3.15) | 0.33 (−1.31 to 1.98) | 0.79 |
| AIx salbutamol, %-units | 7.95 (11.24) | 11.71 (10.80) | 0.82 (−1.12 to 2.75) | −0.64 (−2.41 to 1.12) | 0.61 |
| Tr, ms | 147 (8) | 143 (9) | −1.9 (−3.7 to −0.2) | 0.5 (−1.1 to 2.1) | 0.13 |
| EFI | 0.31 (0.16) | 0.32 (0.16) | 0.04 (−0.04 to 0.12) | 0.02 (−0.06 to 0.08) | 0.85 |
| Office blood pressure, mm Hg | |||||
| Systolic | 151 (15) | 155 (14) | −2.6 (−5.7 to 0.6) | −4.6 (−8.4 to −0.8) | 0.58 |
| Diastolic | 95 (12) | 94 (9) | −1.7 (−3.6 to 0.08) | −3.7 (−6.1 to −1.3) | 0.14 |
| Twenty-four-h blood pressure, mm Hg | |||||
| Systolic | −1.4 (−4.0 to 1.3) | −4·6 (−6.9 to −2.3) | P=0.22 | ||
| Diastolic | −1.5 (−3.3 to 0.3) | −2.7 (−4.2 to −1.2) | P=0.55 | ||
Abbreviations: AIx, the aortic augmentation index; CI, confidence interval; EFI, an endothelial function index; Tr, the time to return of the reflected wave.
a
Analysis of covariance with body mass index and baseline measure as covariates.